These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 25213363

  • 1. The use of biologic therapies in the treatment of rheumatoid arthritis.
    Wang D, Li Y, Liu Y, Shi G.
    Curr Pharm Biotechnol; 2014; 15(6):542-8. PubMed ID: 25213363
    [Abstract] [Full Text] [Related]

  • 2. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR.
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [Abstract] [Full Text] [Related]

  • 3. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N, Betts KA, Messali AJ, Skup M, Garg V.
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [Abstract] [Full Text] [Related]

  • 4. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
    Levesque MC.
    BioDrugs; 2012 Apr 01; 26(2):65-70. PubMed ID: 22385403
    [Abstract] [Full Text] [Related]

  • 5. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ, Hyrich KL.
    BioDrugs; 2009 Apr 01; 23(2):111-24. PubMed ID: 19489652
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M.
    J Rheumatol Suppl; 2009 Jun 01; 82():25-32. PubMed ID: 19509327
    [Abstract] [Full Text] [Related]

  • 9. Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile.
    Luchetti MM, Balloni A, Gabrielli A.
    Curr Drug Saf; 2016 Jun 01; 11(1):22-34. PubMed ID: 26463246
    [Abstract] [Full Text] [Related]

  • 10. Biologic agents in rheumatoid arthritis: an update for managed care professionals.
    Agarwal SK.
    J Manag Care Pharm; 2011 Jun 01; 17(9 Suppl B):S14-8. PubMed ID: 22073935
    [Abstract] [Full Text] [Related]

  • 11. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.
    Singh JA, Cameron DR.
    J Manag Care Pharm; 2012 May 01; 18(4 Supp C):S1-18. PubMed ID: 22656072
    [Abstract] [Full Text] [Related]

  • 12. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D.
    Ann Rheum Dis; 2020 Jun 01; 79(6):685-699. PubMed ID: 31969328
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biologic therapies and bone loss in rheumatoid arthritis.
    Zerbini CAF, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Uña CR, Adachi JD, Lems WF, Cooper C, Lane NE, IOF Chronic Inflammation and Bone Structure (CIBS) Working Group.
    Osteoporos Int; 2017 Feb 01; 28(2):429-446. PubMed ID: 27796445
    [Abstract] [Full Text] [Related]

  • 15. Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.
    Singh JA.
    Curr Rheumatol Rep; 2016 Oct 01; 18(10):61. PubMed ID: 27613285
    [Abstract] [Full Text] [Related]

  • 16. Strategies toward rheumatoid arthritis therapy; the old and the new.
    Abbasi M, Mousavi MJ, Jamalzehi S, Alimohammadi R, Bezvan MH, Mohammadi H, Aslani S.
    J Cell Physiol; 2019 Jul 01; 234(7):10018-10031. PubMed ID: 30536757
    [Abstract] [Full Text] [Related]

  • 17. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis.
    Alfonso-Cristancho R, Armstrong N, Arjunji R, Riemsma R, Worthy G, Ganguly R, Kleijnen J.
    Clin Rheumatol; 2017 Jan 01; 36(1):25-34. PubMed ID: 27726046
    [Abstract] [Full Text] [Related]

  • 18. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK, Rafiq A, Östör AJ.
    Clin Rheumatol; 2015 Dec 01; 34(12):2141-5. PubMed ID: 26497501
    [Abstract] [Full Text] [Related]

  • 19. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N, Lee YC, Shah N, Harrison DJ.
    Clin Ther; 2014 Aug 01; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [Abstract] [Full Text] [Related]

  • 20. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.
    Shan J, Zhang J.
    Joint Bone Spine; 2019 Mar 01; 86(2):173-183. PubMed ID: 29635017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.